Abbott Laboratories

  • Earnings Score
  • Moat Score
  • Safety Score
  • Final Score
  • Market Cap $234.76B
  • PE 18
  • Debt $15.63B
  • Cash $7.62B
  • EV $242.77B
  • FCF $6.35B

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings$13.35B
EBIT$7.01B
ROE28%
ROA9%
FCF$6.35B
Equity$47.90B
Growth Stability93%
PE17.58
PEG1.36
PB4.9
P/FCF36.96
P/S5.6
Price/Cash0.03
Debt/Equity0.33
Debt/FCF2.46
Net Margins32%
Gross Margins55%
Op. Margins17%
Earnings CAGR28%
Sales Growth YoY7%
Sales Growth QoQ3%
Sales CAGR9%
FCF CAGR15%
Equity CAGR7%
Earnings Stability0.64
Earnings Growth YoY479%
Earnings Growth QoQ461%
Earnings CAGR 5Y13%
Sales CAGR 5Y5%
FCF CAGR 5Y-0%
Equity CAGR 5Y7%
Earnings CAGR 3Y-4%
Sales CAGR 3Y-4%
FCF CAGR 3Y-15%
Equity CAGR 3Y7%
Market Cap$234.76B
Revenue$41.95B
Dividend Yield2%
Payout Ratio29%
Assets$81.41B
Total Debt$15.63B
Cash$7.62B
Shares Outstanding1.74B
EV242.77B
Earnings Score90%
Moat Score94%
Safety Score93%
Final Score92%
Working Capital9.5B
Current Ratio1.67
Gross Profit$23.24B
Shares Growth 3y-0%
Equity Growth QoQ20%
Equity Growth YoY23%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.

SEC Filings

Direct access to Abbott Laboratories (ABT) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2024
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2023
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2022
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31

Sector Comparison

How does Abbott Laboratories compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Abbott Laboratories compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 28%
Stability 64%
loading chart...

Abbott Laboratories Discounted Cash Flow

Fully customizable DCF calculator online for Abbott Laboratories.

= $182B
012345678910TV
fcf$6.4B$7.3B$8.4B$9.7B$11B$13B$15B$17B$20B$22B$26B$259B
DCF$6.6B$7B$7.3B$7.6B$8B$8.3B$8.7B$9.1B$9.5B$10B$100B
Value$182B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years12/201512/201612/201712/201812/201912/202012/202112/202212/202312/2024TTM
Net Margins22%7%2%8%11%13%16%16%14%32%32%
ROA-6%3%5%7%7%11%11%9%9%9%
ROE-7%2%8%12%14%20%19%15%28%28%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years12/201512/201612/201712/201812/201912/202012/202112/202212/202312/2024TTM
Debt over FCF-11.986.363.994.273.282.172.443.122.462.46
Debt over Equity0.421.060.910.640.610.570.520.520.410.330.33
Growth Stability---100%100%100%100%100%93%100%93%

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years12/201512/201612/201712/201812/201912/202012/202112/202212/202312/2024CAGR 5Y
Revenue YoY growth-2%31%12%4%8%24%1%-8%5%5%
Earnings YoY growth--68%-66%403%56%22%57%-2%-17%134%13%
Equity YoY growth--3%50%-1%2%5%9%2%5%23%7%
FCF YoY growth-14%141%11%-8%27%51%-10%-35%26%-0%